Differential effects of 17β-estradiol, conjugated equine estrogen, and raloxifene on mRNA expression, aggregation, and secretion in platelets

Muthuvel Jayachandran, Rajarshi Mukherjee, Thomas Steinkamp, Peter LaBreche, Margarita P. Bracamonte, Hiroya Okano, Whyte G. Owen, Virginia M Miller

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Changes in platelet functions could contribute to thrombotic risk associated with estrogen treatments. This study was designed to test the hypothesis that three clinically relevant estrogenic treatments affect platelet function comparably. Adult female pigs were ovariectomized and randomized to either no treatment or treatment with oral 17β-estradiol (2 mg/day), conjugated equine estrogen (0.625 mg/day), or raloxifene (60 mg/day) for 4 wk. Platelet turnover, aggregation, and secretion were assessed before and after treatment. Platelet turnover and mRNA increased significantly only in pigs treated with 17β-estradiol. Expression of estrogen receptors increased with ovariectomy and decreased with all treatments. Platelet aggregation and secretion of ATP, platelet-derived growth factor, and matrix metalloproteinase-2 increased with ovariectomy. All treatments reduced both aggregation and secretion. Expression of mRNA for constitutive endothelial nitric oxide synthase (eNOS), but not eNOS protein, increased with ovariectomy. Only eNOS mRNA decreased with all treatments, but only treatment with 17β-estradiol increased secretion of nitric oxide from intact platelets. Platelets from 17β-estradiol-treated animals caused relaxation of coronary arteries, which was sensitive to inhibition of nitric oxide. Although three different estrogenic treatments reversed increases in platelet aggregation caused by ovariectomy, only 17β-estradiol increased platelet RNA and release of platelet-derived nitric oxide. These differences reflect transcriptional and posttranscriptional regulation of protein synthesis in bone marrow megakaryocytes and circulating platelets.

Original languageEnglish (US)
JournalAmerican Journal of Physiology - Heart and Circulatory Physiology
Volume288
Issue number5 57-5
DOIs
StatePublished - May 2005

Fingerprint

Conjugated (USP) Estrogens
Estradiol
Blood Platelets
Messenger RNA
Ovariectomy
Nitric Oxide Synthase Type III
Platelet Aggregation
Nitric Oxide
Swine
Megakaryocytes
Raloxifene Hydrochloride
Matrix Metalloproteinase 2
Platelet-Derived Growth Factor
Estrogen Receptors
Coronary Vessels
Estrogens
Proteins
Adenosine Triphosphate
Bone Marrow
RNA

Keywords

  • Hormones
  • Matrix metalloproteinase
  • Nitric oxide
  • Thrombosis

ASJC Scopus subject areas

  • Physiology

Cite this

Differential effects of 17β-estradiol, conjugated equine estrogen, and raloxifene on mRNA expression, aggregation, and secretion in platelets. / Jayachandran, Muthuvel; Mukherjee, Rajarshi; Steinkamp, Thomas; LaBreche, Peter; Bracamonte, Margarita P.; Okano, Hiroya; Owen, Whyte G.; Miller, Virginia M.

In: American Journal of Physiology - Heart and Circulatory Physiology, Vol. 288, No. 5 57-5, 05.2005.

Research output: Contribution to journalArticle

Jayachandran, Muthuvel ; Mukherjee, Rajarshi ; Steinkamp, Thomas ; LaBreche, Peter ; Bracamonte, Margarita P. ; Okano, Hiroya ; Owen, Whyte G. ; Miller, Virginia M. / Differential effects of 17β-estradiol, conjugated equine estrogen, and raloxifene on mRNA expression, aggregation, and secretion in platelets. In: American Journal of Physiology - Heart and Circulatory Physiology. 2005 ; Vol. 288, No. 5 57-5.
@article{db0b53b7c70e4542bb2423e2ed27ccbc,
title = "Differential effects of 17β-estradiol, conjugated equine estrogen, and raloxifene on mRNA expression, aggregation, and secretion in platelets",
abstract = "Changes in platelet functions could contribute to thrombotic risk associated with estrogen treatments. This study was designed to test the hypothesis that three clinically relevant estrogenic treatments affect platelet function comparably. Adult female pigs were ovariectomized and randomized to either no treatment or treatment with oral 17β-estradiol (2 mg/day), conjugated equine estrogen (0.625 mg/day), or raloxifene (60 mg/day) for 4 wk. Platelet turnover, aggregation, and secretion were assessed before and after treatment. Platelet turnover and mRNA increased significantly only in pigs treated with 17β-estradiol. Expression of estrogen receptors increased with ovariectomy and decreased with all treatments. Platelet aggregation and secretion of ATP, platelet-derived growth factor, and matrix metalloproteinase-2 increased with ovariectomy. All treatments reduced both aggregation and secretion. Expression of mRNA for constitutive endothelial nitric oxide synthase (eNOS), but not eNOS protein, increased with ovariectomy. Only eNOS mRNA decreased with all treatments, but only treatment with 17β-estradiol increased secretion of nitric oxide from intact platelets. Platelets from 17β-estradiol-treated animals caused relaxation of coronary arteries, which was sensitive to inhibition of nitric oxide. Although three different estrogenic treatments reversed increases in platelet aggregation caused by ovariectomy, only 17β-estradiol increased platelet RNA and release of platelet-derived nitric oxide. These differences reflect transcriptional and posttranscriptional regulation of protein synthesis in bone marrow megakaryocytes and circulating platelets.",
keywords = "Hormones, Matrix metalloproteinase, Nitric oxide, Thrombosis",
author = "Muthuvel Jayachandran and Rajarshi Mukherjee and Thomas Steinkamp and Peter LaBreche and Bracamonte, {Margarita P.} and Hiroya Okano and Owen, {Whyte G.} and Miller, {Virginia M}",
year = "2005",
month = "5",
doi = "10.1152/ajpheart.01108.2004",
language = "English (US)",
volume = "288",
journal = "American Journal of Physiology - Renal Fluid and Electrolyte Physiology",
issn = "1931-857X",
publisher = "American Physiological Society",
number = "5 57-5",

}

TY - JOUR

T1 - Differential effects of 17β-estradiol, conjugated equine estrogen, and raloxifene on mRNA expression, aggregation, and secretion in platelets

AU - Jayachandran, Muthuvel

AU - Mukherjee, Rajarshi

AU - Steinkamp, Thomas

AU - LaBreche, Peter

AU - Bracamonte, Margarita P.

AU - Okano, Hiroya

AU - Owen, Whyte G.

AU - Miller, Virginia M

PY - 2005/5

Y1 - 2005/5

N2 - Changes in platelet functions could contribute to thrombotic risk associated with estrogen treatments. This study was designed to test the hypothesis that three clinically relevant estrogenic treatments affect platelet function comparably. Adult female pigs were ovariectomized and randomized to either no treatment or treatment with oral 17β-estradiol (2 mg/day), conjugated equine estrogen (0.625 mg/day), or raloxifene (60 mg/day) for 4 wk. Platelet turnover, aggregation, and secretion were assessed before and after treatment. Platelet turnover and mRNA increased significantly only in pigs treated with 17β-estradiol. Expression of estrogen receptors increased with ovariectomy and decreased with all treatments. Platelet aggregation and secretion of ATP, platelet-derived growth factor, and matrix metalloproteinase-2 increased with ovariectomy. All treatments reduced both aggregation and secretion. Expression of mRNA for constitutive endothelial nitric oxide synthase (eNOS), but not eNOS protein, increased with ovariectomy. Only eNOS mRNA decreased with all treatments, but only treatment with 17β-estradiol increased secretion of nitric oxide from intact platelets. Platelets from 17β-estradiol-treated animals caused relaxation of coronary arteries, which was sensitive to inhibition of nitric oxide. Although three different estrogenic treatments reversed increases in platelet aggregation caused by ovariectomy, only 17β-estradiol increased platelet RNA and release of platelet-derived nitric oxide. These differences reflect transcriptional and posttranscriptional regulation of protein synthesis in bone marrow megakaryocytes and circulating platelets.

AB - Changes in platelet functions could contribute to thrombotic risk associated with estrogen treatments. This study was designed to test the hypothesis that three clinically relevant estrogenic treatments affect platelet function comparably. Adult female pigs were ovariectomized and randomized to either no treatment or treatment with oral 17β-estradiol (2 mg/day), conjugated equine estrogen (0.625 mg/day), or raloxifene (60 mg/day) for 4 wk. Platelet turnover, aggregation, and secretion were assessed before and after treatment. Platelet turnover and mRNA increased significantly only in pigs treated with 17β-estradiol. Expression of estrogen receptors increased with ovariectomy and decreased with all treatments. Platelet aggregation and secretion of ATP, platelet-derived growth factor, and matrix metalloproteinase-2 increased with ovariectomy. All treatments reduced both aggregation and secretion. Expression of mRNA for constitutive endothelial nitric oxide synthase (eNOS), but not eNOS protein, increased with ovariectomy. Only eNOS mRNA decreased with all treatments, but only treatment with 17β-estradiol increased secretion of nitric oxide from intact platelets. Platelets from 17β-estradiol-treated animals caused relaxation of coronary arteries, which was sensitive to inhibition of nitric oxide. Although three different estrogenic treatments reversed increases in platelet aggregation caused by ovariectomy, only 17β-estradiol increased platelet RNA and release of platelet-derived nitric oxide. These differences reflect transcriptional and posttranscriptional regulation of protein synthesis in bone marrow megakaryocytes and circulating platelets.

KW - Hormones

KW - Matrix metalloproteinase

KW - Nitric oxide

KW - Thrombosis

UR - http://www.scopus.com/inward/record.url?scp=18044364454&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18044364454&partnerID=8YFLogxK

U2 - 10.1152/ajpheart.01108.2004

DO - 10.1152/ajpheart.01108.2004

M3 - Article

C2 - 15653758

AN - SCOPUS:18044364454

VL - 288

JO - American Journal of Physiology - Renal Fluid and Electrolyte Physiology

JF - American Journal of Physiology - Renal Fluid and Electrolyte Physiology

SN - 1931-857X

IS - 5 57-5

ER -